{"id":"F2014L00746","name":"Therapeutic Goods (Listing) Notice 2014 (No. 1)","slug":"therapeutic-goods-listing-notice-2014-no-1","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":91954,"registerId":"commonwealth-F2014L00746-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Therapeutic Goods (Listing) Notice 2014 (No. 1)","content":"Therapeutic Goods Act 1989\n\nTherapeutic Goods (Listing) Notice 2014 (No. 1)\n\nI, JOHN SKERRITT, National Manager of the Therapeutic Goods Administration, delegate of the Minister for Health for the purposes of subsection 9A(5) of the Therapeutic Goods Act 1989 (the Act) and acting under that provision, require the following therapeutic goods to be included in the part of the Australian Register of Therapeutic Goods (the Register) for listed goods:\n\n-   preparations, for the purpose of Item 3 of Part 1 of Schedule 4 to the Therapeutic Goods Regulations 1990 (the Regulations), that contain ‘Menaquinone 7’ as a therapeutically active ingredient, subject to the following conditions:\n\n-   the preparations are for oral use only; and\n-   the preparations provide not more than 180 g of ‘menaquinone 7’ per daily dose in adults; and\n-   the preparations provide not more than 90 g of ‘menaquinone 7’ per daily dose in children between 10 to 18 years of age; and\n-   the preparations provide not more than 45 g of ‘menaquinone 7’ per daily dose in children less than 10 years of age.\n\nThis Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.\n\nPursuant to subsection 9A(6) of the Act, this Notice ceases to have effect on the day that amendments to the Regulations come into effect to require inclusion of the therapeutic goods listed in this Notice in the part of the Register for listed goods.\n\nDated this 18th day of May 2014\n\n(Signed by)\n\nJohn Skerritt\n\nDelegate of the Minister for Health","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":1830},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"The instrument maintains its original narrow scope of temporarily listing Menaquinone 7 preparations with specific age-based dosage restrictions until permanent regulations can be made."},"complexity_factors":["Single active ingredient specified with no chemical modifications or variants","Only four explicit conditions (administration route and three age-based dosage limits)","No definitions section or interpretation provisions","Minimal cross-referencing (only cites the enabling Act and Regulations)","Temporary operation with automatic expiry upon regulatory amendment"],"plain_english_summary":"This notice temporarily approves vitamin K2 (menaquinone‑7) supplements as listed therapeutic goods on the ARTG, allowing their sale in Australia and affecting manufacturers, importers and over‑the‑counter consumers.\n\nApproved products must be oral and meet maximum daily doses—adults 180 µg, ages 10–18 90 µg, under 10 45 µg. The approval is interim pending permanent regulation; this notice is the current legal authority for these supplements."}},"importantCases":[],"_links":{"self":"/api/acts/therapeutic-goods-listing-notice-2014-no-1","history":"/api/acts/therapeutic-goods-listing-notice-2014-no-1/history","analysis":"/api/acts/therapeutic-goods-listing-notice-2014-no-1/analysis","conflicts":"/api/acts/therapeutic-goods-listing-notice-2014-no-1/conflicts","importantCases":"/api/acts/therapeutic-goods-listing-notice-2014-no-1/important-cases","documents":"/api/acts/therapeutic-goods-listing-notice-2014-no-1/documents"}}